Clinical trials · Raleigh–Durham, NC
Refractory Diffuse Large B-Cell Lymphoma clinical trials in Raleigh–Durham
We’re tracking 8 recruiting refractory diffuse large b-cell lymphoma studies with a site in or near Raleigh–Durham — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Raleigh–Durham
- NCT05633615RecruitingPhase 2
Testing new drug options after CAR T for aggressive lymphoma
This Phase 2 study tests whether adding or switching drug treatments after CAR T-cell therapy can improve outcomes for people with certain aggressive lymphomas that have come back or did not respond. It mainly looks at who remains disease-stable/partly improved after CAR T and what treatment approach works best next.
Durham, North CarolinaAges 18 years+ - NCT06649812RecruitingPhase 2
Testing a combination targeted therapy (ViPOR) for aggressive B-cell lymphoma
This trial tests a new combination of targeted drugs called ViPOR for people with aggressive B-cell lymphoma that has come back or not responded to previous treatment. The goal is to see if this treatment can help when standard therapies haven't worked.
Durham, North CarolinaAges 18 years+ - NCT07188558RecruitingPhase 3
Comparing ronde-cel to standard CAR T-cell therapy for large B-cell lymphoma
This trial tests a new treatment called ronde-cel against the usual CAR T-cell therapy for people with large B-cell lymphoma that has come back or not responded to initial treatment. The goal is to see if ronde-cel works better.
Durham, North CarolinaAges 18 years+ - NCT06116110Recruiting
Long-term follow-up after gene therapy treatment
This study is a long-term follow-up for people who previously received a gene therapy treatment called zamtocabtagene autoleucel in a Miltenyi Biomedicine-sponsored clinical study. It helps researchers monitor your health over time after the treatment.
Durham, North CarolinaAges 18 years+ - NCT04792489RecruitingPhase 2
CAR-T cell therapy for aggressive B-cell lymphomas
This trial tests a new CAR-T cell treatment (MB-CART2019.1) for people with certain types of aggressive B-cell non-Hodgkin lymphoma, including diffuse large B-cell lymphoma (DLBCL) that has come back or not responded to prior treatments. It aims to see if this therapy can help when other options have failed.
Durham, North CarolinaAges 18 years+ - NCT06091865RecruitingPhase 3
Testing odronextamab with chemo for untreated DLBCL
This trial is testing a new drug called odronextamab combined with chemotherapy against the standard treatment for people with previously untreated DLBCL. The goal is to see if the new combination works better and is safe.
Durham, North CarolinaAges 18 years+ - NCT04775745RecruitingPhase 1
Oral drug test for relapsed or refractory B-cell blood cancers
This Phase 1 trial studies LP-168 taken by mouth in people whose B-cell cancers have come back or did not respond to treatment. The study aims to find how the drug works, the right dose, and what side effects to expect.
Durham, North CarolinaAges 18 years+ - NCT06533579RecruitingPhase 1/Phase 2
Gene therapy for CD19-positive blood cancers
This trial tests a new gene therapy treatment for people with certain types of leukemia or lymphoma that have the CD19 marker and have not responded to other treatments. The therapy uses a virus to deliver a gene to target and kill cancer cells.
Chapel Hill, North CarolinaAges 13–90
Hear when a new Refractory Diffuse Large B-Cell Lymphoma trial opens near Raleigh–Durham, NC
We’ll email you when one opens near Raleigh–Durham, NC — at most once a week, no account needed, unsubscribe anytime.
Refractory Diffuse Large B-Cell Lymphoma trials in other cities
Where these studies are running near Raleigh–Durham
Institutions with a site for the recruiting refractory diffuse large b-cell lymphoma studies listed above.
- Duke University Medical Center · 6 studies
- Duke Cancer Institute
- University of North Carolina at Chapel Hill
What taking part in a refractory diffuse large b-cell lymphoma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting refractory diffuse large b-cell lymphoma studies in North Carolina.
Common questions
- Are there refractory diffuse large b-cell lymphoma clinical trials near Raleigh–Durham?
- Yes. We're currently tracking 8 recruiting refractory diffuse large b-cell lymphoma studies with a site near Raleigh–Durham, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a refractory diffuse large b-cell lymphoma study near Raleigh–Durham?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Raleigh–Durham to take part?
- Not necessarily. These studies have a site near Raleigh–Durham, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a refractory diffuse large b-cell lymphoma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New refractory diffuse large b-cell lymphoma studies open near Raleigh–Durham regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.